Table 2.
Patient characteristics of durable responders (PFS >24 months) and non-durable responders (PFS <24 months)
| Clinical characteristics | Durable responders: PFS >24 months (N=150) | Non-durable responders: PFS <24 months (N=1040) | P value |
| Age at diagnosis | 69.0 (59.0; 75.0) | 68.0 (61.0; 75.0) | 0.714 |
| Practice type | 0.703 | ||
| Academic | 13 (8.67%) | 77 (7.40%) | |
| Community | 137 (91.3%) | 963 (92.6%) | |
| Gender | 0.791 | ||
| Female | 75 (50.0%) | 504 (48.5%) | |
| Male | 75 (50.0%) | 536 (51.5%) | |
| Self-reported race | 0.250 | ||
| White | 108 (72.0%) | 717 (68.9%) | |
| Black or African American | 15 (10.0%) | 83 (7.98%) | |
| Missing | 10 (6.67%) | 74 (7.12%) | |
| Other race | 17 (11.33%) | 166 (16.0%) | |
| Histology | 0.012 | ||
| Non-squamous cell carcinoma | 124 (82.7%) | 748 (71.9%) | |
| NSCLC histology NOS | 7 (4.67%) | 50 (4.81%) | |
| Squamous cell carcinoma | 19 (12.7%) | 242 (23.3%) | |
| Stage | 0.728 | ||
| I | 15 (10.0%) | 84 (8.08%) | |
| II | 10 (6.67%) | 89 (8.56%) | |
| III | 22 (14.7%) | 171 (16.4%) | |
| IV | 100 (66.7%) | 682 (65.6%) | |
| Unknown | 3 (2.00%) | 14 (1.35%) | |
| History of smoking | 0.427 | ||
| History of smoking | 137 (91.3%) | 972 (93.5%) | |
| No history of smoking | 13 (8.67%) | 68 (6.54%) | |
| PD-L1 (TS) | <0.001 | ||
| <1% | 31 (20.7%) | 365 (35.1%) | |
| 1–49% | 33 (22.0%) | 308 (29.6%) | |
| ≥50% | 86 (57.3%) | 367 (35.3%) | |
| TMB | <0.001 | ||
| <10 | 68 (45.3%) | 660 (63.5%) | |
| 10~20 | 44 (29.3%) | 292 (28.1%) | |
| ≥20 | 38 (25.3%) | 88 (8.46%) | |
| Therapy class | 0.187 | ||
| ICPI | 67 (44.7%) | 402 (38.7%) | |
| ChemoICPI | 83 (55.3%) | 638 (61.3%) |
chemoICPI, ICPI with chemotherapy; ICPI, immune checkpoint inhibitors; NOS, not otherwise specified; NSCLC, non-small cell lung cancer; PD-L1, programmed death ligand-1; PFS, progression-free survival; TMB, tumor mutational burden; TS, tumor staining.